Trial Information
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
Inclusion Criteria:
- treatment-naive patients with lymphoma
- HBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline
- treated with chemotherapy and/or immunosuppressive therapy
- life expectancy of more than 3 months
Exclusion Criteria:
- younger than 18 years old
- HBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline
- pregnant or lactating women
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis
Outcome Time Frame:
from the beginning of anti-tumor therapy to 18 months after the last cycle of anti-tumor therapy
Safety Issue:
Yes
Principal Investigator
Jun Zhu
Investigator Role:
Principal Investigator
Investigator Affiliation:
Peking University Cancer Hospital & Institute
Authority:
China: Ethics Committee
Study ID:
PKU-2012111305
NCT ID:
NCT01765231
Start Date:
January 2013
Completion Date:
Related Keywords:
- Hepatitis B
- Lymphoma
- Hepatitis B virus
- Therapeutic Uses
- Antiviral Agents
- Hepatitis
- Hepatitis A
- Hepatitis B
- Lymphoma